Evidence map›Paper›PMID 37885502›Full record

ArticleCureus2023

An Uncommon Side Effect of Rivaroxaban: A Drug-Induced Liver Injury.

Bhesh R Karki, Ranjit B Jasaraj, Suman K Jha, Nodari Maisuradze, Qi Yu

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Bhesh R KarkiInternal Medicine, State University of New York (SUNY) Downstate Health Sciences University, New York City, USA.
Ranjit B JasarajInternal Medicine, Mount Sinai Hospital Medical Center of Chicago, Chicago, USA.
Suman K JhaFamily Medicine, University of North Dakota, Fargo, USA.
Nodari MaisuradzeInternal Medicine, State University of New York (SUNY) Downstate Health Sciences University, New York City, USA.
Qi YuGastroenterology and Hepatology, State University of New York (SUNY) Downstate Health Sciences University, New York City, USA.
SUNY Downstate Health Sciences University · USMount Sinai Hospital · US

Funding

Clinical Research Scholars Training (CREST) ProgramR25MD017950 · NIMHD · SUNY DOWNSTATE MEDICAL CENTER · PI Carla Boutin-Foster, Marlene Camacho · 2022 to 2026
$2.6M
NIMHD NIH HHS R25 MD017950
6 · The paper itself

Abstract

Rivaroxaban is rarely associated with drug-induced liver injury (DILI). A 57-year-old male was sent to the emergency room from an endocrine clinic for a presyncope evaluation. His exam was non-focal, and his laboratory work was remarkable for the hepatocellular pattern of liver injury. Upon detailed assessment, he was found to have DILI due to rivaroxaban. The liver function tests improved after its discontinuation. This case emphasizes the need for early recognition and timely intervention to prevent further hepatotoxicity from the culprit drug.

Indexed as

deranged liver function testsdirect oral anticoagulantdrug induced liver injuryelevated transaminaseshepatotoxicityrivaroxaban

Identifiers

PMID37885502
PMCPMC10599792
OpenAlexW4387009446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.